PBP Stock Overview
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast-moving consumer products in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for PBP from our risk checks.
My Notes
NewNotes are coming soon
Probiotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.23 |
| 52 Week High | AU$2.42 |
| 52 Week Low | AU$2.02 |
| Beta | 0.44 |
| 1 Month Change | 1.36% |
| 3 Month Change | 3.24% |
| 1 Year Change | 0.45% |
| 3 Year Change | -8.61% |
| 5 Year Change | 159.30% |
| Change since IPO | 93.07% |
Recent News & Updates
Shareholder Returns
| PBP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 2.3% | -3.6% | 0.8% |
| 1Y | 0.5% | -29.0% | 2.2% |
Return vs Industry: PBP exceeded the Australian Pharmaceuticals industry which returned -29% over the past year.
Return vs Market: PBP underperformed the Australian Market which returned 2.2% over the past year.
Price Volatility
| PBP volatility | |
|---|---|
| PBP Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.5% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PBP is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PBP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Wes Stringer | https://www.probiotec.com.au |
Probiotec Limited engages in the development, manufacture, packing, and sale of pharmaceuticals, consumer health, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, ointments, and suspensions; powders and powder blending; and sprays, as well as manufactures and packages finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Limited Fundamentals Summary
| PBP fundamental statistics | |
|---|---|
| Market Cap | AU$181.35m |
| Earnings (TTM) | AU$13.71m |
| Revenue (TTM) | AU$182.33m |
13.2x
P/E Ratio1.0x
P/S RatioIs PBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBP income statement (TTM) | |
|---|---|
| Revenue | AU$182.33m |
| Cost of Revenue | AU$125.09m |
| Gross Profit | AU$57.24m |
| Other Expenses | AU$43.53m |
| Earnings | AU$13.71m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 31.39% |
| Net Profit Margin | 7.52% |
| Debt/Equity Ratio | 61.3% |
How did PBP perform over the long term?
See historical performance and comparison